{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:30:25Z","timestamp":1775226625273,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1756-8722-4-53","type":"journal-article","created":{"date-parts":[[2011,12,21]],"date-time":"2011-12-21T14:29:46Z","timestamp":1324477786000},"source":"Crossref","is-referenced-by-count":17,"title":["Pharmacological basis and clinical evidence of dabigatran therapy"],"prefix":"10.1186","volume":"4","author":[{"given":"Santiago","family":"Redondo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Paz","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Ramajo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Navarro-Dorado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abelardo","family":"Barez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Tejerina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,12,21]]},"reference":[{"key":"186_CR1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1160\/TH07-03-0183","volume":"98","author":"W Wienen","year":"2007","unstructured":"Wienen W, Stassen JM, Priepke H: In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007, 98: 155-162.","journal-title":"Thromb Haemost"},{"key":"186_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1182\/blood-2009-09-241851","volume":"115","author":"D Garcia","year":"2010","unstructured":"Garcia D, Libby E, Crowther MA: The new oral anticoagulants. Blood. 2010, 115: 15-20. 10.1182\/blood-2009-09-241851.","journal-title":"Blood"},{"key":"186_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","volume":"47","author":"J Stangier","year":"2008","unstructured":"Stangier J: Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clinical Pharmacokinetis. 2008, 47: 285-295. 10.2165\/00003088-200847050-00001.","journal-title":"Clinical Pharmacokinetis"},{"key":"186_CR4","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1111\/j.1538-7836.2004.00890.x","volume":"2","author":"BI Eriksson","year":"2004","unstructured":"Eriksson BI, Dahl OE, Ahnfelt L, K\u00e4lebo P, Stangier J, Nehmiz G, Hermansson K, Kohlbrenner V: Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost. 2004, 2: 1573-1580. 10.1111\/j.1538-7836.2004.00890.x.","journal-title":"J Thromb Haemost"},{"key":"186_CR5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","volume":"64","author":"J Stangier","year":"2007","unstructured":"Stangier J, Rathgen K, St\u00e4hle H, Gansser D, Roth W: The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharm. 2007, 64: 292-303. 10.1111\/j.1365-2125.2007.02899.x.","journal-title":"Br J Clin Pharm"},{"key":"186_CR6","unstructured":"European Medicines Agency. Dabigatran label. [\n                    http:\/\/www.ema.europa.eu\n                    \n                  ]"},{"key":"186_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1538-7836.2004.01100.x","volume":"3","author":"BI Eriksson","year":"2005","unstructured":"Eriksson BI, Dahl OE, B\u00fcller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, K\u00e4lebo P, Reilly P, BISTRO II Study Group: A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005, 3: 103-111. 10.1111\/j.1538-7836.2004.01100.x.","journal-title":"J Thromb Haemost"},{"key":"186_CR8","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.amjcard.2007.06.034","volume":"100","author":"MD Ezekowitz","year":"2007","unstructured":"Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L: Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007, 100: 1419-1426. 10.1016\/j.amjcard.2007.06.034.","journal-title":"Am J Cardiol"},{"key":"186_CR9","unstructured":"Boerhinger-Ingelheim. Dabigatran Advisory Committee Briefing Document. [\n                    http:\/\/www.fda.org\n                    \n                  ]"},{"key":"186_CR10","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009, 361: 1139-1151. 10.1056\/NEJMoa0905561.","journal-title":"N Engl J Med"},{"key":"186_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","volume":"362","author":"L Wallentin","year":"2003","unstructured":"Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nystr\u00f6m P, Bylock A, ESTEEM Investigators: Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet. 2003, 362: 789-797. 10.1016\/S0140-6736(03)14287-0.","journal-title":"Lancet"},{"key":"186_CR12","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","volume":"5","author":"BI Eriksson","year":"2007","unstructured":"Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, K\u00e4lebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, B\u00fcller HR, RE-MODEL Study Group: Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007, 5: 2178-2185. 10.1111\/j.1538-7836.2007.02748.x.","journal-title":"J Thromb Haemost"},{"key":"186_CR13","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","volume":"370","author":"BI Eriksson","year":"2007","unstructured":"Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, B\u00fcller HR, RE-NOVATE Study Group: Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007, 370: 949-956. 10.1016\/S0140-6736(07)61445-7.","journal-title":"Lancet"},{"key":"186_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0883-5403(08)00955-8","volume":"24","author":"JS Ginsberg","year":"2009","unstructured":"Ginsberg JS, Davidson BL, Comp PC, RE-MOBILIZE Writing Committee, RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA: Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009, 24: 1-9.","journal-title":"J Arthroplasty"},{"key":"186_CR15","first-page":"175","volume":"126","author":"RJ Friedman","year":"2010","unstructured":"Friedman RJ, Dahl OE, Rosencher N, Caprini JA, Kurth AA, Francis CW, Clemens A, Hantel S, Schnee JM, Eriksson BI, RE-MOBILIZE, RE-NOVATE Steering Committees: Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials. J Thromb Haemost. 2010, 126: 175-182.","journal-title":"J Thromb Haemost"},{"key":"186_CR16","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, RE-COVER Study Group: Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. New Engl J Med. 2009, 361: 2342-2352. 10.1056\/NEJMoa0906598.","journal-title":"New Engl J Med"},{"key":"186_CR17","unstructured":"Food and Drug Administration. Dabigatran label. [\n                    http:\/\/www.fda.org\n                    \n                  ]"},{"key":"186_CR18","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1160\/TH09-11-0758","volume":"103","author":"J Van Ryn","year":"2010","unstructured":"Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A: Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010, 103: 1116-1127. 10.1160\/TH09-11-0758.","journal-title":"Thromb Haemost"},{"key":"186_CR19","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.jacc.2011.01.010","volume":"57","author":"LS Wann","year":"2011","unstructured":"Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM: 2011 ACCF\/AHA\/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2011, 57: 1330-1337. 10.1016\/j.jacc.2011.01.010.","journal-title":"J Am Coll Cardiol"},{"key":"186_CR20","volume-title":"J Med Toxicol","author":"M Ganetsky","year":"2011","unstructured":"Ganetsky M, Babu KM, Salhanick SD, Brown RS, Boyer EW: Dabigatran: Review of Pharmacology and Management of Bleeding Complications of This Novel Oral Anticoagulant. J Med Toxicol. 2011,"},{"key":"186_CR21","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","volume":"124","author":"ES Eerenberg","year":"2011","unstructured":"Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M: Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011, 124: 1573-9. 10.1161\/CIRCULATIONAHA.111.029017.","journal-title":"Circulation"},{"key":"186_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","volume":"49","author":"J Stangier","year":"2010","unstructured":"Stangier J, Rathgen K, St\u00e4hle H, Mazur D: Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010, 49: 259-68. 10.2165\/11318170-000000000-00000.","journal-title":"Clin Pharmacokinet"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-4-53.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1756-8722-4-53\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-4-53.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T17:18:49Z","timestamp":1548177529000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-4-53"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["186"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-4-53","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]},"article-number":"53"}}